RESUMO
It is agreed that many of the antitumor effects of (-)-epigallocatechin gallate (EGCG) are mediated by various other effects. We report a new finding, namely, the antiproliferation potential and mechanism of methylated-(3'')-epigallocatechin gallate analog (MethylEGCG) having a stronger anti-oxidation effect than EGCG. MethylEGCG inhibited activity of vascular endothelial growth factor (VEGF)-depended VEGF receptor 2 and p42/44 MAPK, cell proliferation, and tube formation in human umbilical vascular endothelial cells (HUVECs) at 1 µ M. Even low- dose (1.1 mg/kg i.p. 8.3 mg/kg p.o.) administration suppressed tumor growth in xenografted Huh7 hepatoma mice by 50%. CD31 positive cells, visualized in blood vessels, were reduced in tumors by 18%, suggesting high antitumor activity via inhibition of angiogenesis. This study indicated that the modification of the 3'' position methylation of EGCG (MethylEGCG) could reduce cell growth effects at a low concentration in vivo.
Assuntos
Carcinoma Hepatocelular/patologia , Catequina/análogos & derivados , Neovascularização Patológica/tratamento farmacológico , Animais , Antioxidantes/farmacologia , Carcinoma Hepatocelular/metabolismo , Catequina/farmacologia , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular , Células Endoteliais da Veia Umbilical Humana/efeitos dos fármacos , Células Endoteliais da Veia Umbilical Humana/metabolismo , Humanos , Neoplasias Hepáticas/metabolismo , Camundongos , Proteína Quinase 1 Ativada por Mitógeno/genética , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Neovascularização Patológica/patologia , Fator A de Crescimento do Endotélio Vascular/genética , Fator A de Crescimento do Endotélio Vascular/metabolismo , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Clinical evaluation of perioperative IABP use in valvular heart surgery was studied. There were 4 preoperative, 18 intraoperative and 20 postoperative applications of IABP. The indications of IABP were LOS in 19 patients, failed weaning from bypass in 11, life threatening arrhythmia in 11, and congestive heart failure in 1. Sixteen out of 26 patients with successful weaning from IABP support could be discharged. Ten died after removal of IABP. Longer duration of cardiopulmonary bypass and aortic clamp, lower value of cardiac index 24 hours after introduction of IABP support were implicated in unsuccessful IABP support. The causes of death were due to LOS in 8 patients, MOF in 12, GVHD in 2, others in 3. The outcome of IABP for patients with valvular heart surgery was not satisfactory. However, the results of IABP support in valvular surgery will be improved by reducing the incidence of postoperative complications, especially LOS, followed by MOF.
